Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP282229.RABA-jPDMNEUok7pDpab9jL8FiHX3X8c-IBEf0r30UG_0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP282229.RABA-jPDMNEUok7pDpab9jL8FiHX3X8c-IBEf0r30UG_0130_assertion type Assertion NP282229.RABA-jPDMNEUok7pDpab9jL8FiHX3X8c-IBEf0r30UG_0130_head.
- NP282229.RABA-jPDMNEUok7pDpab9jL8FiHX3X8c-IBEf0r30UG_0130_assertion description "[We have developed a cancer-specific immunotherapy called modified CTL therapy, which involves adoptive immunotherapy of autologous cancer-specific bulk CTLs after active immunization of autologous or allogeneic cancer cells screened as in vitro stimulators according to their ability to induce autologous cancer-specific CTLs (ACS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP282229.RABA-jPDMNEUok7pDpab9jL8FiHX3X8c-IBEf0r30UG_0130_provenance.
- NP282229.RABA-jPDMNEUok7pDpab9jL8FiHX3X8c-IBEf0r30UG_0130_assertion evidence source_evidence_literature NP282229.RABA-jPDMNEUok7pDpab9jL8FiHX3X8c-IBEf0r30UG_0130_provenance.
- NP282229.RABA-jPDMNEUok7pDpab9jL8FiHX3X8c-IBEf0r30UG_0130_assertion SIO_000772 11078795 NP282229.RABA-jPDMNEUok7pDpab9jL8FiHX3X8c-IBEf0r30UG_0130_provenance.
- NP282229.RABA-jPDMNEUok7pDpab9jL8FiHX3X8c-IBEf0r30UG_0130_assertion wasDerivedFrom befree-20140225 NP282229.RABA-jPDMNEUok7pDpab9jL8FiHX3X8c-IBEf0r30UG_0130_provenance.
- NP282229.RABA-jPDMNEUok7pDpab9jL8FiHX3X8c-IBEf0r30UG_0130_assertion wasGeneratedBy ECO_0000203 NP282229.RABA-jPDMNEUok7pDpab9jL8FiHX3X8c-IBEf0r30UG_0130_provenance.